Clasado Biosciences will attend Vitafoods Asia 2025, taking place 17-19 September in Bangkok, Thailand.
The event brings together leading nutraceutical brands, formulators, contract manufacturers and academics from across the APAC market, to explore the future of science-backed nutrition. Vitafoods Asia will also see winners of the NutraIngredients Asia awards announced, where Bimuno® GOS is a finalist in the Ingredient: Sports Nutrition category.
Clasado will be in attendance and ready to discuss the very latest prebiotic gut health science. David Mharakurwa, Regional Director for APAC, and Per Rehné, CEO at Clasado, will be available for meetings throughout the show.
Visitors to Vitafoods Asia 2025 are invited to get in touch and arrange a meeting with David and Per at the exhibition.
David said: “Across the Asia-Pacific region, interest in gut health is stronger than ever, with consumers seeking simple, convenient and science-backed ways to support their wellbeing. Within this, sports nutrition is a fast-growing category, as active consumers look for gut health solutions that fit seamlessly into training and recovery, with efficacy as the foundation.
“As an ingredient with strong clinical backing and now proven efficacy at ultra-low doses, Bimuno GOS is ideally suited to what brands in this region are looking to create. Our recognition in sports nutrition, winning Ingredient of the Year at the NutraIngredients USA Awards 2025 and now being named a finalist at the NutraIngredients Asia Awards, highlights the impact of our science in this category. We are looking forward to connecting with formulators at Vitafoods Asia to explore how we can support their innovation goals.”
Per added: “The nutraceutical market moves quickly, and events like Vitafoods are a perfect opportunity to explore the very latest advances in functional ingredient technology. We will be there, meeting with formulators to discuss where prebiotics fit into the future of health and wellbeing, with sports nutrition being a key part of that conversation.
“We will have a particular focus on our new ultra-low dose research, which confirms that Bimuno GOS delivers a bifidogenic effect from just 380mg daily – one of the lowest efficacious prebiotic doses reported to date. This creates exciting potential for formulators developing small-format nutraceuticals or layering Bimuno GOS into multi-ingredient products.”
To learn more about Bimuno GOS and the science behind it, click here.
